Clinical effect and safety of 144-week treatment with entecavir capsules in treatment-naïve HBeAg-positive patients with chronic hepatitis B
10.3760/cma.j.issn.1007-3418.2017.08.008
- VernacularTitle: 恩替卡韦胶囊治疗HBeAg阳性慢性乙型肝炎初治患者144周的有效性和安全性
- Author:
Dachuan CAI
1
;
Chen PAN
2
;
Weihua YU
3
;
Shuangsuo DANG
4
;
Jia LI
5
;
Shanming WU
6
;
Nan JIANG
7
;
Maorong WANG
8
;
Zhaohua ZHANG
9
;
Feng LIN
10
;
Shaojie XIN
11
;
Yongfeng YANG
12
;
Baoshen SHEN
13
;
Hong REN
1
Author Information
1. The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China
2. Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350000, China
3. The Eighth People's Hospital of Guangzhou, Guangzhou 510060, China
4. The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710004, China
5. The Second People's Hospital of Tianjin, Tianjin 300192, China
6. Shanghai Public Health Clinical Center, Shanghai 201508, China
7. Sichuan Provincial People's Hospital, Chengdu 610772, China
8. No.81 Hospital of PLA, Nanjing 210002, China
9. Jinan Infectious Disease Hospital, Jinan 250021, China
10. Hainan General Hospital, Haikou 570311, China
11. No.302 Hospital of PLA, Beijing 100039, China
12. The Second Hospital of Nanjing, Nanjing 210003, China
13. The First Affiliated Hospital of Xinxiang Medical University, Xinxiang 453100, China
- Publication Type:Journal Article
- Keywords:
Entecavir capsule;
Efficacy;
Safety
- From:
Chinese Journal of Hepatology
2017;25(8):597-600
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical effect and safety of entecavir capsules in the treatment of treatment-naïve HBeAg-positive patients with chronic hepatitis B (CHB).
Methods:A total of 158 HBeAg-positive CHB patients were given oral entecavir capsules at a dose of 0.5 mg/time once a day for 144 weeks. Clinical outcome and safety were evaluated at baseline and at 24, 48, 72, 96, 120, and 144 weeks of treatment respectively. The Fisher’s exact test was used for the analysis of categorical data.
Results:After 144 weeks of treatment, 90.91% of all patients achieved virologic response (< 69 IU/ml), the normalization rate of alanine aminotransferase was 88.18%, the clearance rate of HBeAg was 33.33%, and the seroconversion rate of HBeAg was 24.07%. Of all patients, 2 dropped out due to adverse events and 5 experienced serious adverse reactions.
Conclusion:Entecavir capsules can inhibit viral replication and have good safety in treatment-naïve HBeAg-positive CHB patients.
